Emerging Company Profile
Exo: expanding the universe of druggable enzymes
Emerging Company Profile: David Liu’s latest newco launches with $25M to develop small molecules against non-catalytic, non-allosteric enzyme sites
David Liu’s latest start-up launches with $25 million to discover small molecules against non-catalytic, non-allosteric sites that influence substrate docking.
Dec 17, 2020 | 12:50 AM GMT
Exo debuted Wednesday with $25 million in series A funding to broaden